Original Article

You have full text access to this OnlineOpen article

Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

  1. Francis J. Giles M.D.1,†,*,
  2. Maureen A. Cooper M.D.2,
  3. Lewis Silverman M.D.3,
  4. Judith E. Karp M.D.4,
  5. Jeffrey E. Lancet M.D.5,
  6. Maurizio Zangari M.D.6,
  7. Paul J. Shami M.D.7,
  8. Khuda D. Khan M.D.2,
  9. Alison L. Hannah M.D.8,‡,
  10. Julie M. Cherrington Ph.D.8,
  11. Deborah A. Thomas M.D.1,
  12. Guillermo Garcia-Manero M.D.1,
  13. Maher Albitar M.D.1,
  14. Hagop M. Kantarjian M.D.1,
  15. Alison T. Stopeck M.D.9

Article first published online: 1 APR 2003

DOI: 10.1002/cncr.11315

Issue

Cancer

Cancer

Volume 97, Issue 8, pages 1920–1928, 15 April 2003

Additional Information

How to Cite

Giles, F. J., Cooper, M. A., Silverman, L., Karp, J. E., Lancet, J. E., Zangari, M., Shami, P. J., Khan, K. D., Hannah, A. L., Cherrington, J. M., Thomas, D. A., Garcia-Manero, G., Albitar, M., Kantarjian, H. M. and Stopeck, A. T. (2003), Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases. Cancer, 97: 1920–1928. doi: 10.1002/cncr.11315

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Indianapolis Community Cancer Center, Indianapolis, Indiana

  3. 3

    Division of Medical Oncology, Mount Sinai Medical Center, New York, New York

  4. 4

    University of Maryland Greenbaum Cancer Center, Baltimore, Maryland

  5. 5

    James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York

  6. 6

    University of Arkansas for Medical Sciences, Little Rock, Arkansas

  7. 7

    University of Utah and Salt Lake City Veterans Administration Medical Centers, Salt Lake City, Utah

  8. 8

    Sugen Inc., South San Francisco, California

  9. 9

    Arizona Cancer Center, Tucson, Arizona

  1. †

    Fax: (713) 794-4297

  2. ‡

    Dr. Hannah is a consultant for Sugen Inc.

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030

Publication History

  1. Issue published online: 1 APR 2003
  2. Article first published online: 1 APR 2003
  3. Manuscript Accepted: 30 DEC 2002
  4. Manuscript Revised: 13 DEC 2002
  5. Manuscript Received: 23 OCT 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (104K)

REFERENCES

  • 1
    Di Raimondo F, Palumbo GA, Molica S, Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 2001; 106: 177–183.
  • 2
    Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997; 150: 815–821.
  • 3
    Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000; 342: 1255–1265.
  • 4
    Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000; 96: 3374–3380.
  • 5
    Diamond T, Smith A, Schnier R, Manoharan A. Syndrome of myelofibrosis and osteosclerosis: a series of case reports and review of the literature. Bone. 2002; 30: 498–501.
  • 6
    Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000; 157: 15–19.
  • 7
    Thiele J, Rompcik V, Wagner S, Fischer R. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br J Haematol. 1992; 80: 227–234.
  • 8
    Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96: 2240–2245.
  • 9
    Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001; 106: 170–176.
  • 10
    Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely “preleukemia.” Blood. 2002; 100: 791–798.
  • 11
    Korkolopoulou P, Apostolidou E, Pavlopoulos PM, et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001; 15: 1369–1376.
  • 12
    Moehler TM, Neben K, Ho AD, Goldschmidt H. Angiogenesis in hematologic malignancies. Ann Hematol. 2001; 80: 695–705.
  • 13
    Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999; 81: 1398–1401.
  • 14
    Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001; 49: 568–581.
  • 15
    Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 1997; 94: 8761–8766.
  • 16
    Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002; 118: 151–156.
    Direct Link:
  • 17
    Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 2000; 26: 561–569.
  • 18
    Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001; 15: 976–980.
  • 19
    Musolino C, Calabro L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol. 2002; 69: 159–163.
    Direct Link:
  • 20
    Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002; 16: 1609–1614.
  • 21
    Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res. 2002; 11: 119–125.
  • 22
    Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001; 97: 1427–1434.
  • 23
    Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002; 16: 1302–1310.
  • 24
    Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 2001; 6 (Suppl 5): 32–39.
  • 25
    Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol. 2000; 53: 188–193.
  • 26
    Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991; 78: 2962–2968.
  • 27
    Kuriu A, Ikeda H, Kanakura Y, et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 1991; 78: 2834–2840.
  • 28
    Kimura A, Nakata Y, Katoh O, Hyodo H. c-kit Point mutation in patients with myeloproliferative disorders. Leuk Lymphoma. 1997; 25: 281–287.
  • 29
    Nakata Y, Kimura A, Katoh O, et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol. 1995; 91: 661–663.
    Direct Link:
  • 30
    Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma. 2000; 37: 473–486.
  • 31
    Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997; 89: 1870–1875.
  • 32
    Cambier N, Baruchel A, Schlageter MH, et al. Chronic myelomonocytic leukemia: from biology to therapy. Hematol Cell Ther. 1997; 39: 41–48.
  • 33
    Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000; 6: 4848–4858.
  • 34
    Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol. 2001; 53: 1629–1636.
    Direct Link:
  • 35
    Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999; 59: 99–106.
  • 36
    Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia. 1999; 1: 31–41.
  • 37
    Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999; 59: 5412–5416.
  • 38
    Yee KW, O'Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase. Blood. 2002; 100: 2941–2949.
  • 39
    Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001; 97: 1413–1421.
  • 40
    Spiekermann K, Faber F, Voswinckel R, Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol. 2002; 30: 767–773.
  • 41
    Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000; 108: 322–330.
    Direct Link:
  • 42
    Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000; 96: 3907–3914.
  • 43
    Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000; 14: 1766–1776.
  • 44
    Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001; 98: 1752–1759.
  • 45
    Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001; 37: 1590–1598.
  • 46
    Michaud LB. Methods for preventing reactions secondary to Cremophor EL. Ann Pharmacother. 1997; 31: 1402–1404.
  • 47
    Antonian L, Zhang H, Yang C, et al. Biotransformation of the anti-angiogenic compound SU5416. Drug Metab Disp. 2000; 28: 1505–1512.
  • 48
    Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol. 1997; 37 (5 Pt 1): 765–771.
  • 49
    Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother. 1995; 29: 906–917.
  • 50
    Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ. 2002; 167: 279–280.
  • 51
    Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164–172.
  • 52
    Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002; 99: 3547–3553.
  • 53
    Angelov L, Salhia B, Roncari L, McMahon G, Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 1999; 59: 5536–5541.
  • 54
    Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000; 15: 29–41.
  • 55
    Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001; 19: 265–272.
  • 56
    Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 1997; 57: 3924–3928.
  • 57
    Desai SB, Libutti SK. Tumor angiogenesis and endothelial cell modulatory factors. J Immunother. 1999; 22: 186–211.
  • 58
    Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res. 1996; 69: 135–174.
  • 59
    Dalley A, Smith JM, Reilly JT, Neil SM. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol. 1996; 93: 856–862.
    Direct Link:
  • 60
    Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997; 97: 441–448.
    Direct Link:
  • 61
    Le Bousse-Kerdiles MC, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996; 88: 4534–4546.
  • 62
    Wang JC, Chen C, Lou LH, Mora M. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia. 1997; 11: 1827–1832.
  • 63
    Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Antiangiogenic therapy in leukemia. Acta Haematol. 2001; 106: 190–207.
  • 64
    Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001; 114: 78–83.
    Direct Link:
  • 65
    Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol. 2001; 115: 313–315.
    Direct Link:
  • 66
    Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002; 117: 288–296.
    Direct Link:
  • 67
    Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica. 2001; 86: 772–773.
  • 68
    Baidas S, Tfayli A, Bhargava P. Thalidomide: an old drug with new clinical applications. Cancer Invest. 2002; 20: 835–848.
  • 69
    Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol. 2000; 12: 564–573.
  • 70
    Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol. 1996; 81: 219–223.
  • 71
    Beran M, O'Brien S, Andersson B, McCredie KB, Gutterman JU. Tumor necrosis factor and human hematopoiesis: II. Inhibition and mode of action on normal and chronic myelogenous leukemia-derived granulocyte-macrophage progenitor cells. Hematol Pathol. 1988; 2: 65–71.
  • 72
    Tsimberidou AM, Thomas D, O'Brien S, et al. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002; 50: 237–242.
  • 73
    Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther. 2002; 2: 277–286.
  • 74
    Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000; 60: 2178–2189.
  • 75
    Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002; 99: 3885–3891.
  • 76
    Fiedler WM, Tinnefeld H, Mende T, et al. A Phase II study with SU5416 in patients with c-kit positive AML. Proc Am Soc Clin Oncol. 2001; 20: 288a.
View Full Article (HTML) Get PDF (104K)